PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

• ClinicalTrials.gov Identifier: NCT01734512
• Recruitment Status: Active, not recruiting
• First Posted: November 27, 2012
• Results First Posted: February 18, 2021
• Last Update Posted: December 27, 2023
• Sponsor: University of California, San Francisco
• Collaborators: Novartis Pharmaceuticals; Pacific Pediatric Neuro-Oncology Consortium; The Pediatric Low Grade Astrocytoma (PLGA) Foundation
• Information provided by (Responsible Party): University of California, San Francisco

Study Description

Brief Summary:

This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.

Condition or disease	Intervention/treatment	Phase
Pediatric Recurrent Progressive Low-grade Gliomas; Pediatric Progressive Low-grade Gliomas	Drug: Everolimus	Phase 2

Detailed Description:

This is an open label study of everolimus in children with recurrent or progressive low-grade glioma. All patients will receive everolimus at a dose of 5 mg/m2/dose daily. An adaptive Simon two-stage design for phase 2 studies of targeted therapies will be used to assess the efficacy primary objective. The proposed treatment with everolimus will be deemed not worthy of further investigation in this patient population if the true PFS at 6-months (PFS6) is less than 50%. If in the first stage, with a combined sample size of 25, there is preliminary evidence to suggest efficacy of everolimus is restricted to patients with PI3K/AKT/mTOR activation as measured by p-S6 positivity, a total of 45 patients will be enrolled and the design will have 81% statistical power to detect a true disease stabilization rate ≥70%. If in the first stage there is preliminary evidence to suggest efficacy of everolimus is independent of PI3K/AKT/mTOR activation, a total of 65 patients will be enrolled and the design will have >95% statistical power to detect a true disease stabilization rate ≥70%.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 65 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
• Actual Study Start Date: December 13, 2012
• Actual Primary Completion Date: January 31, 2020
• Estimated Study Completion Date: July 31, 2024

Arms and Interventions

Arm

Intervention/treatment

Experimental: Everolimus; Everolimus tablet will be taken daily by mouth with water. Twenty-eight days will constitute one course and subsequent courses will immediately follow with no break in the administration of the drug. Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Patients will also be provided with a drug diary for everolimus. The maximum time on study is 24-months, but if there is no disease progression or adverse events, the patient may speak with a doctor about continuing the treatment off-study.

Drug: Everolimus; Everolimus tablet will be taken daily by mouth with water. All patients will be given a dose of 5 mg/m2/dose daily.

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants With Progression Free Survival at 6 Months [ Time Frame: Up to 6 months ]
   Response was be determined by bi-dimensional diameters. RECIST criteria will be collected and used for secondary evaluation. Patients will have brain MRI scans with and without gadolinium performed prior to therapy, after every second course in the first year, after every third course in the second year, and at the End of Study visit (if not done within prior 3 months). Spine MRIs should be performed prior to therapy and at the same time points as standard brain MRIs if clinically indicated.

Secondary Outcome Measures :

1. Proportion of Participants With Objective Response [ Time Frame: Up to 6 months ]
   The proportion of participants who demonstrated a complete or partial response as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1 Criteria where complete Response (CR) is defined as the complete disappearance of all known disease for >=8 weeks. Complete response is dated from time all lesions have disappeared on a stable or decreasing dose of corticosteroids. A Partial Response (PR) is a reduction of at least 50% in the size of all measurable tumor as quantitated by sum of the products of the largest diameters (SLD) of measurable lesions and maintained for >=8 weeks on a stable or decreasing dose of corticosteroids. Partial response is dated from the time of first observation. Overall response also takes into account the response in both the target and non-target lesion, and the appearance of new lesions, where applicable and depend on the achievement of both measurement and confirmation criteria.
2. Median Progression Free Survival in Recurrent Pediatric Low-grade Glioma (LGGs) [ Time Frame: Up to 5 years ]
   Progression free survival will be calculated from date of first treatment to the date of first observation of progressive disease, non-reversible neurological progression or increasing steroid requirements (applies to stable disease only), death due to any cause, or early discontinuation of treatment
3. Median Overall Survival in Recurrent Pediatric LGGs [ Time Frame: Up to 5 years ]
   Overall survival will be calculated from date of original diagnoses to death and also from the date of study registration to death. The latter will be an endpoint for assessment of benefit of this therapy.

Eligibility Criteria

• Ages Eligible for Study: 3 Years to 21 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

--Patients must have radiographic progressive or recurrent confirmed world health organization (WHO) grade I or II astrocytomas, that was confirmed histologically. Progressive or recurrent disease should be based on MRI according to the definition below.

Eligible histologies:

• Pilocytic Astrocytoma - 90600112
• Astrocytoma, Low Grade (Fibrillary astrocytoma, WHO Grade 2) - 10065886

• Astrocytoma, Low Grade (Low-grade Astrocytoma, not otherwise specified (NOS), WHO Grade 2) - 10003571

  • Tissue from the initial diagnosis or recurrence must be made available for correlative testing.
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least two dimensions on MRI.
  • Patients may have had treatment (chemotherapy and/or radiotherapy) for any number of relapses prior to this recurrence.
  • Patients must have received their last dose of myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration or at least six (6)weeks of nitrosourea.
  • Patients must have received their last dose of other investigational or biological agent > 7 days prior to study entry.

For agents that have known adverse events occurring beyond 7 days after administration, this period should be extended beyond the time during which adverse events are known to occur. This should be discussed with the study chair.

• If patients received prior monoclonal antibody treatment, at least three half-lives must be elapsed by the time of treatment initiation. These patients should also be discussed with the study chair.

• Patients must have received their last fraction of craniospinal or focal radiation to primary tumor or other sites >12 weeks (3 months) prior to registration.

  --Age ≥3 and ≤21 years.

• Because no dosing or adverse event data are currently available on the use of everolimus in patients <3 years of age, these young children are excluded from this study.

  • Life expectancy of greater than 8 weeks.
  • Patients must be able to swallow pills.
  • Patient must have a Karnofsky (if ≥ 16 years of age) or Lansky Performance score (if ≤ 16 years of age) of ≥50 by the time of registration.
  • Patients must have adequate bone marrow function (ANC ≥ 1,000/mm3, platelet count of ≥ 100,000/mm3, and hemoglobin ≥ 9 gm/dL) before starting therapy. Eligibility level for hemoglobin may be reached by transfusion.
  • International Normalized Ratio (INR) ≤1.5. (Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of low molecular weight (LMW) heparin for >2 weeks at time of randomization).
  • Patients must have adequate liver function (SGPT/alanine aminotransferase (ALT) ≤ 2.5 times ULN and bilirubin ≤ 1.5 times ULN) before starting therapy.
  • Patients must have adequate renal function (serum creatinine ≤ 1.5 times institutional ULN for age or Glomerular filtration rate (GFR) ≥ 70 ml/min/1.73 m2) before starting therapy.
  • Patients must have cholesterol level <350 mg/dL and triglycerides < 400 mg/dL before starting therapy. In case one or both of these are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication and documentation of cholesterol < 350mg/dL and triglycerides < 400mg/dl before start of therapy.
  • Patients must have normal pulmonary function testing for age based on pulse oximetry.
  • The effects of everolimus on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because everolimus are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Female patients of child bearing potential must not be breastfeeding or pregnant as evidenced by a negative pregnancy test.

Exclusion Criteria:

• Patients with primary spinal cord tumors
• Patients receiving concomitant medication that may interfere with study outcome. For example, patients cannot be on enzyme inducing anticonvulsants like phenytoin.
• Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period. Close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus. Examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacille Calmette-Guerin (BCG), yellow fever, varicella and TY21a typhoid vaccines
• Hepatitis B/C blood test must be done at screening for all patients. Patients who test positive for Hepatitis C antibodies and the Hepatitis B antigen are ineligible.
• A known history of HIV seropositivity. HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with everolimus. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.
• Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
• Patients may not have therapy for this recurrence (including radiation).
• Patients who do not have measurable disease on MRI.
• Patients who have been previously treated with an mTOR inhibitor.
• Patients with a known hypersensitivity to everolimus or other rapamycins (e.g. sirolimus, temsirolimus).
• Patients receiving any other concurrent anticancer or investigational therapy.
• Patients with any clinically significant unrelated systemic illness that would compromise the patient's ability to tolerate protocol therapy.
• Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection.
• Patients with inability to return for follow-up visits to assess toxicity to therapy.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years.

Note: A detailed assessment of Hepatitis B/C medical history and risk factors must be done at screening for all patients. Hepatitis B Virus (HBV) DNA and Hepatitis C Virus (HCV) RNA Polymerase chain reaction (PCR) testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection.

Contacts and Locations

Locations

United States, California

Children's Hospital Los Angeles

Los Angeles, California, United States, 90027

University of California, Los Angeles

Los Angeles, California, United States, 90027

Children's Hospital Oakland

Oakland, California, United States, 94609

University of California, San Diego Rady Children's Hospital

San Diego, California, United States, 92123

University of California, San Francisco

San Francisco, California, United States, 94158

United States, District of Columbia

Children's National Medical Center

Washington, District of Columbia, United States, 20010

United States, Florida

University of Florida

Gainesville, Florida, United States, 32611

United States, Illinois

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States, 60611

United States, Maryland

Johns Hopkins University

Baltimore, Maryland, United States, 21218

United States, Massachusetts

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

United States, Minnesota

Children's Hospitals and Clinics of Minneapolis

Minneapolis, Minnesota, United States, 55404

United States, Missouri

St. Louis Children's Hospital, Washington University

Saint Louis, Missouri, United States, 63130

United States, Ohio

Nationwide Children's Hospital

Columbus, Ohio, United States, 43205

United States, Oregon

Oregon Health & Science University

Portland, Oregon, United States, 97239

United States, Pennsylvania

The Children's Hospital Of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

United States, Tennessee

St. Jude Children's Research Hospital

Memphis, Tennessee, United States, 38105

United States, Utah

University of Utah

Salt Lake City, Utah, United States, 84112

United States, Washington

University of Washington, Seattle

Seattle, Washington, United States, 98195

Sponsors and Collaborators

University of California, San Francisco

Novartis Pharmaceuticals

Pacific Pediatric Neuro-Oncology Consortium

The Pediatric Low Grade Astrocytoma (PLGA) Foundation

Investigators

• Study Chair: Daphne Haas-Kogan, MD; Dana-Farber Cancer Institute
• Principal Investigator: Sabine Mueller, MD; University of California, San Francisco

  Study Documents (Full-Text)

Documents provided by University of California, San Francisco:

Study Protocol and Statistical Analysis Plan  [PDF] January 7, 2019

More Information

• Responsible Party: University of California, San Francisco
• ClinicalTrials.gov Identifier: NCT01734512
• Other Study ID Numbers: 120817; NCI-2012-02774 ( Registry Identifier: NCI Clinical Trials Reporting Program (CTRP) )
• First Posted: November 27, 2012
• Results First Posted: February 18, 2021
• Last Update Posted: December 27, 2023
• Last Verified: December 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by University of California, San Francisco:

pediatric recurrent progressive low-grade gliomas; pediatric progressive low-grade gliomas; everolimus; mTOR inhibition

Additional relevant MeSH terms:

Glioma; Recurrence; Disease Attributes; Pathologic Processes; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Everolimus; MTOR Inhibitors; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antineoplastic Agents